molsidomine has been researched along with Disease Models, Animal in 44 studies
Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies." | 7.79 | The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013) |
| "Molsidomine (Mol) is a drug used for the treatment of coronary artery disease." | 5.32 | Molsidomine ameliorates experimental allergic encephalomyelitis in Lewis rats. ( Choi, BM; Chung, HT; Jang, SI; Jung, S; Kwak, HJ; Oh, GS; Pae, HO, 2003) |
| "The cardioprotective and antithrombotic activity of molsidomine, a novel therapeutic agent for the treatment of coronary heart disease, was investigated in a series of animal models of myocardial ischemia." | 4.77 | The activity of molsidomine in experimental models of ischemic cardiac disease. ( Martorana, PA; Nitz, RE, 1985) |
| " The aim of our research was to compare molsidomine, SIN-1, SIN-1A, and lidocaine influence on arrhythmias and hemodynamic parameters in 2 experimental models in rats." | 3.85 | New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology. ( Krzemiński, TF; Mitręga, KA; Porc, M; Żorniak, M, 2017) |
| "Thus, in our model of chronic renocardiac syndrome, combined treatments similarly decreased cardiac fibrosis and stabilized systolic function as losartan alone, perhaps suggesting a dominant role for a single factor such as angiotensin II type 1 (AT1) receptor activation or inflammation in the network of aberrant systems in the heart." | 3.85 | Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation. ( Bongartz, LG; Braam, B; Cheng, C; Cramer, MJ; Doevendans, PA; Gaillard, CA; Goldschmeding, R; Joles, JA; Oosterhuis, NR; van Koppen, A; Verhaar, MC; Xu, YJ, 2017) |
| " We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican-null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies." | 3.79 | The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. ( Brunelli, S; Campana, L; Clementi, E; Cottone, L; Querini, PR; Sciorati, C; Zordan, P, 2013) |
| "The IOP lowering effects of NCX 139, a new chemical entity comprising latanoprost amide and a NO-donating moiety, were compared to those of the respective des-nitro analog in in vitro assays and in rabbit and dog models of ocular hypertension." | 3.77 | A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs. ( Batugo, M; Borghi, V; Brambilla, S; Carreiro, ST; Chiroli, V; Chong, WK; Gale, DC; Guzzetta, M; Impagnatiello, F; Krauss, AH; Ongini, E; Prasanna, G, 2011) |
| "Molsidomine tended to increase MAP duration by 20." | 1.37 | Nitric oxide delays atrial tachycardia-induced electrical remodelling in a sheep model. ( Heidbüchel, H; Holemans, P; Janssens, S; Lenaerts, I; Pokreisz, P; Sipido, KR; Willems, R, 2011) |
| "In the treatment of pulmonary hypertension, this pathway is exogenously activated using inhaled NO or other pharmacological agents." | 1.37 | Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration. ( Aggarwal, S; Black, SM; Datar, S; Fineman, JR; Fratz, S; Gross, CM; Kalkan, G; Kumar, S; Oishi, P; Schreiber, C, 2011) |
| "Molsidomine (Mol) is a drug used for the treatment of coronary artery disease." | 1.32 | Molsidomine ameliorates experimental allergic encephalomyelitis in Lewis rats. ( Choi, BM; Chung, HT; Jang, SI; Jung, S; Kwak, HJ; Oh, GS; Pae, HO, 2003) |
| "4." | 1.32 | The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats. ( de Dam, MY; Elmedal, B; Mulvany, MJ; Simonsen, U, 2004) |
| "Oral treatment with molsidomine (MSDM), a NO donor, began 24 h before IRBP immunization to the end of the experiments, which resulted in a significant inhibition of the disease by clinical and histopathological criteria." | 1.31 | Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response. ( Chung, HT; Kim, YM; Kwak, HJ; Pae, HO; Yang, YS, 2001) |
| " The differences between aorto-caval fistula rats and sham operated rats were probably the result of increased basal EDRF-NO release in the former, since NO synthase blockade abolished the differences in both aortic cGMP and the dose-response curve to Sin-1." | 1.29 | Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure. ( Arnal, JF; Michel, JB; Schott, C; Stoclet, JC, 1993) |
| "Molsidomine is a prodrug of nitric oxide (NO) and is used in the treatment of coronary heart disease." | 1.29 | Effect of molsidomine and free radical scavengers on the pulmonary thromboembolism in mice. ( Dikshit, M; Seth, P; Srimal, RC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.82) | 18.7374 |
| 1990's | 7 (15.91) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 17 (38.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Fang, Q | 1 |
| Wang, M | 2 |
| Wang, W | 2 |
| Zhang, M | 1 |
| Zhang, D | 1 |
| He, Y | 1 |
| Zhang, Y | 1 |
| Wang, H | 1 |
| Otero, M | 1 |
| Ma, T | 1 |
| Chen, J | 1 |
| Samdanci, ET | 1 |
| Huz, M | 1 |
| Ozhan, O | 1 |
| Tanbek, K | 1 |
| Pamukcu, E | 1 |
| Akatli, AN | 1 |
| Parlakpinar, H | 1 |
| Schaefer, ML | 1 |
| Perez, PJ | 1 |
| Coca Peralta, W | 1 |
| Xu, J | 1 |
| Johns, RA | 1 |
| Zordan, P | 1 |
| Sciorati, C | 1 |
| Campana, L | 1 |
| Cottone, L | 1 |
| Clementi, E | 1 |
| Querini, PR | 1 |
| Brunelli, S | 1 |
| Solís, O | 1 |
| Espadas, I | 1 |
| Del-Bel, EA | 1 |
| Moratalla, R | 1 |
| Gao, Y | 1 |
| Heldt, SA | 1 |
| Chung, E | 1 |
| Ohgami, Y | 1 |
| Quock, RM | 1 |
| Żorniak, M | 1 |
| Mitręga, KA | 1 |
| Porc, M | 1 |
| Krzemiński, TF | 1 |
| Oosterhuis, NR | 1 |
| Bongartz, LG | 2 |
| Verhaar, MC | 2 |
| Cheng, C | 1 |
| Xu, YJ | 1 |
| van Koppen, A | 1 |
| Cramer, MJ | 2 |
| Goldschmeding, R | 3 |
| Gaillard, CA | 2 |
| Doevendans, PA | 2 |
| Braam, B | 3 |
| Joles, JA | 3 |
| Urtasun, R | 1 |
| Cubero, FJ | 1 |
| Vera, M | 1 |
| Nieto, N | 1 |
| Pitsikas, N | 2 |
| Kupershmidt, L | 1 |
| Weinreb, O | 1 |
| Amit, T | 1 |
| Mandel, S | 1 |
| Carri, MT | 1 |
| Youdim, MB | 1 |
| Boultadakis, A | 1 |
| Liakos, P | 1 |
| Miguel, TL | 1 |
| Pobbe, RL | 1 |
| Spiacci Junior, A | 1 |
| Zangrossi Junior, H | 1 |
| Steendijk, P | 1 |
| Fan, Q | 1 |
| Yang, XC | 1 |
| Liu, Y | 1 |
| Wang, LF | 1 |
| Liu, SH | 1 |
| Ge, YG | 1 |
| Chen, ML | 1 |
| Zhang, LK | 1 |
| Irwin, MG | 1 |
| Xia, Z | 1 |
| Lenaerts, I | 1 |
| Holemans, P | 1 |
| Pokreisz, P | 1 |
| Sipido, KR | 1 |
| Janssens, S | 1 |
| Heidbüchel, H | 1 |
| Willems, R | 1 |
| Aggarwal, S | 1 |
| Gross, CM | 1 |
| Kumar, S | 1 |
| Datar, S | 1 |
| Oishi, P | 1 |
| Kalkan, G | 1 |
| Schreiber, C | 1 |
| Fratz, S | 1 |
| Fineman, JR | 1 |
| Black, SM | 1 |
| Impagnatiello, F | 1 |
| Borghi, V | 1 |
| Gale, DC | 1 |
| Batugo, M | 1 |
| Guzzetta, M | 1 |
| Brambilla, S | 1 |
| Carreiro, ST | 1 |
| Chong, WK | 1 |
| Prasanna, G | 1 |
| Chiroli, V | 1 |
| Ongini, E | 1 |
| Krauss, AH | 1 |
| Hung, LW | 1 |
| Villemagne, VL | 1 |
| Cheng, L | 1 |
| Sherratt, NA | 1 |
| Ayton, S | 1 |
| White, AR | 1 |
| Crouch, PJ | 1 |
| Lim, S | 1 |
| Leong, SL | 1 |
| Wilkins, S | 1 |
| George, J | 1 |
| Roberts, BR | 1 |
| Pham, CL | 1 |
| Liu, X | 1 |
| Chiu, FC | 1 |
| Shackleford, DM | 1 |
| Powell, AK | 1 |
| Masters, CL | 1 |
| Bush, AI | 1 |
| O'Keefe, G | 1 |
| Culvenor, JG | 1 |
| Cappai, R | 1 |
| Cherny, RA | 1 |
| Donnelly, PS | 1 |
| Hill, AF | 1 |
| Finkelstein, DI | 1 |
| Barnham, KJ | 1 |
| Kwak, HJ | 2 |
| Pae, HO | 2 |
| Oh, GS | 1 |
| Choi, BM | 1 |
| Jang, SI | 1 |
| Jung, S | 1 |
| Chung, HT | 2 |
| Elmedal, B | 1 |
| de Dam, MY | 1 |
| Mulvany, MJ | 1 |
| Simonsen, U | 1 |
| Kina, VA | 1 |
| Villarreal, CF | 1 |
| Prado, WA | 1 |
| Lozano, FS | 1 |
| López-Novoa, JM | 1 |
| Rodriguez, JM | 1 |
| Barros, MB | 1 |
| García-Criado, FJ | 1 |
| Nicolás, JL | 1 |
| Parreño, A | 1 |
| Revilla, J | 1 |
| Gómez-Alonso, A | 1 |
| Yang, C | 1 |
| Hader, W | 1 |
| Zhang, X | 1 |
| Kaundal, RK | 1 |
| Shah, KK | 1 |
| Sharma, SS | 1 |
| Lau, A | 1 |
| Arundine, M | 1 |
| Sun, HS | 1 |
| Jones, M | 1 |
| Tymianski, M | 1 |
| Falk, JA | 1 |
| Aune, SE | 1 |
| Kutala, VK | 1 |
| Kuppusamy, P | 1 |
| Angelos, MG | 1 |
| Siegemund, M | 1 |
| Van Bommel, J | 1 |
| Sinaasappel, M | 1 |
| Schwarte, LA | 1 |
| Studer, W | 1 |
| Girard, T | 1 |
| Vollebregt, K | 1 |
| Ince, C | 1 |
| Koeners, MP | 1 |
| van der Giezen, DM | 1 |
| Weichert, W | 1 |
| Pauliks, V | 1 |
| Breddin, HK | 1 |
| Fiedler, VB | 1 |
| Kienbaum, P | 1 |
| Braun, M | 1 |
| Hohlfeld, T | 1 |
| Weber, AA | 1 |
| Sarbia, M | 1 |
| Schrör, K | 1 |
| Arnal, JF | 1 |
| Schott, C | 1 |
| Stoclet, JC | 1 |
| Michel, JB | 1 |
| Dikshit, M | 1 |
| Seth, P | 1 |
| Srimal, RC | 1 |
| Richard, V | 1 |
| Blanc, T | 1 |
| Kaeffer, N | 1 |
| Tron, C | 1 |
| Thuillez, C | 1 |
| Fouyas, IP | 1 |
| Kelly, PA | 1 |
| Ritchie, IM | 1 |
| Whittle, IR | 1 |
| Krzaścik, P | 1 |
| Kostowski, W | 1 |
| Cochran, JB | 1 |
| Genovese, F | 1 |
| Ogura, S | 1 |
| Teti, G | 1 |
| Cook, JA | 1 |
| Blumberg, FC | 1 |
| Wolf, K | 1 |
| Sandner, P | 1 |
| Lorenz, C | 1 |
| Riegger, GA | 1 |
| Pfeifer, M | 1 |
| Okamoto, T | 1 |
| Masuda, Y | 1 |
| Kawasaki, T | 1 |
| Yang, YS | 1 |
| Kim, YM | 1 |
| Rolland, PH | 1 |
| Bartoli, JM | 1 |
| Piquet, P | 1 |
| Mekkaoui, C | 1 |
| Nott, SH | 1 |
| Moulin, G | 1 |
| Amabile, P | 1 |
| Mesana, T | 1 |
| Nitz, RE | 1 |
| Martorana, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow[NCT01825369] | Phase 1 | 0 participants (Actual) | Interventional | 2014-12-31 | Withdrawn (stopped due to Changes to cardiac surgery program) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for molsidomine and Disease Models, Animal
| Article | Year |
|---|---|
The activity of molsidomine in experimental models of ischemic cardiac disease.
Topics: Animals; Coronary Circulation; Coronary Disease; Disease Models, Animal; Dogs; Electric Stimulation; | 1985 |
1 trial available for molsidomine and Disease Models, Animal
| Article | Year |
|---|---|
Postconditioning attenuates myocardial injury by reducing nitro-oxidative stress in vivo in rats and in humans.
Topics: Aged; Angioplasty, Balloon, Coronary; Animals; Apoptosis; Disease Models, Animal; Dose-Response Rela | 2011 |
42 other studies available for molsidomine and Disease Models, Animal
| Article | Year |
|---|---|
FGF8 and FGFR3 are up-regulated in hypertrophic chondrocytes: Association with chondrocyte death in deep zone of Kashin-Beck disease.
Topics: Animals; Biomarkers; Cartilage, Articular; Cell Death; Cell Differentiation; Cell Line; Child; Child | 2018 |
Cytoprotective effects of molsidomine against methotrexate-induced hepatotoxicity: an experimental rat study.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Chemical and Drug Induced Liver Injury; Cytoprotection | 2019 |
Nitric Oxide Donor Prevents Neonatal Isoflurane-induced Impairments in Synaptic Plasticity and Memory.
Topics: Anesthetics, Inhalation; Animals; Animals, Newborn; Disease Models, Animal; Female; Isoflurane; Male | 2019 |
The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy.
Topics: Animals; Disease Models, Animal; Fibrosis; Humans; Immunity, Innate; Inflammation; Mice; Molsidomine | 2013 |
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice.
Topics: Animals; Antiparkinson Agents; Benserazide; Cell Count; Corpus Striatum; Disease Models, Animal; Dop | 2015 |
Lack of neuronal nitric oxide synthase results in attention deficit hyperactivity disorder-like behaviors in mice.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Avoidance Learning; Disease Models, Animal; | 2015 |
Increasing the availability of l-arginine and nitric oxide increases sensitivity of nitrous oxide (N2O)-insensitive inbred mice to N2O-induced antinociception.
Topics: Abdominal Pain; Analgesics; Analysis of Variance; Animals; Arginine; Disease Models, Animal; Dose-Re | 2016 |
New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
Topics: Animals; Anti-Asthmatic Agents; Arrhythmias, Cardiac; Creatine Kinase; Disease Models, Animal; Hemod | 2017 |
Targeting multiple pathways reduces renal and cardiac fibrosis in rats with subtotal nephrectomy followed by coronary ligation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cardio-Renal Syndrome; Coronary Vess | 2017 |
Reactive nitrogen species switch on early extracellular matrix remodeling via induction of MMP1 and TNFalpha.
Topics: Actins; Animals; Apoptosis; Carbon Tetrachloride; Cell Line; Cell Proliferation; Cells, Cultured; Co | 2009 |
The nitric oxide (NO) donor molsidomine antagonizes scopolamine and L-NAME-induced performance deficits in a spatial memory task in the rat.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory | 2009 |
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Different | 2009 |
The nitric oxide-releasing derivative of ferulic acid NCX 2057 antagonized delay-dependent and scopolamine-induced performance deficits in a recognition memory task in the rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Butanes; Coumaric Acids; Disease Models, Animal; Dr | 2010 |
Dorsal raphe nucleus regulation of a panic-like defensive behavior evoked by chemical stimulation of the rat dorsal periaqueductal gray matter.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Escape Reaction; Homocystei | 2010 |
The nitric oxide donor molsidomine rescues cardiac function in rats with chronic kidney disease and cardiac dysfunction.
Topics: Administration, Oral; Animals; Biomarkers; Cardiotonic Agents; Creatinine; Disease Models, Animal; G | 2010 |
Nitric oxide delays atrial tachycardia-induced electrical remodelling in a sheep model.
Topics: Action Potentials; Animals; Blood Pressure; Calcium; Calcium Channels, L-Type; Cardiac Pacing, Artif | 2011 |
Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration.
Topics: Administration, Inhalation; Animals; Animals, Newborn; Cells, Cultured; Cyclic GMP; Cyclic GMP-Depen | 2011 |
A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
Topics: Amides; Animals; Antihypertensive Agents; Aorta; Bimatoprost; Chromatography, High Pressure Liquid; | 2011 |
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Line, Tumor; Cognition; Coordination Complexes; Disease Models, Anima | 2012 |
Molsidomine ameliorates experimental allergic encephalomyelitis in Lewis rats.
Topics: Animals; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Immunohisto | 2003 |
The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Acetylcholine; Administration, O | 2004 |
The effects of intraspinal L-NOARG or SIN-1 on the control by descending pathways of incisional pain in rats.
Topics: Analgesia; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Efferent Pathways; Ele | 2005 |
Exogenous nitric oxide modulates the systemic inflammatory response and improves kidney function after risk-situation abdominal aortic surgery.
Topics: Animals; Aortic Aneurysm, Abdominal; Creatinine; Disease Models, Animal; Intercellular Adhesion Mole | 2005 |
Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite.
Topics: Adrenalectomy; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Axons; Brain Diseases; | 2006 |
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Cell Survival; Disease Models, Animal; DNA Fragmentation; | 2006 |
Inhibition of caspase-mediated apoptosis by peroxynitrite in traumatic brain injury.
Topics: Animals; Apoptosis; Blotting, Western; Brain Injuries; Caspases; Cells, Cultured; Cerebral Cortex; C | 2006 |
Inhibition of peroxynitrite precursors, NO and O2, at the onset of reperfusion improves myocardial recovery.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Free Radical Scavengers; Male; Molsidomine; Myoc | 2007 |
The NO donor SIN-1 improves intestinal-arterial P(CO(2)) gap in experimental endotoxemia: an animal study.
Topics: Animals; Arteries; Blood Pressure; Carbon Dioxide; Disease Models, Animal; Endotoxemia; Intestines; | 2007 |
A perinatal nitric oxide donor increases renal vascular resistance and ameliorates hypertension and glomerular injury in adult fawn-hooded hypertensive rats.
Topics: Animals; Animals, Newborn; Blood Pressure; Disease Models, Animal; Female; Glomerular Filtration Rat | 2008 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Hepari | 1983 |
Effects of molsidomine on coronary artery thrombosis and myocardial ischemia in acute canine experiments.
Topics: Animals; Blood Coagulation; Coronary Disease; Disease Models, Animal; Dogs; Female; Hemodynamics; Ma | 1981 |
Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function.
Topics: Acetylcholine; Administration, Oral; Animals; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; C | 1995 |
Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure.
Topics: Acetylcholine; Animals; Atrial Natriuretic Factor; Calcimycin; Cyclic GMP; Disease Models, Animal; D | 1993 |
Effect of molsidomine and free radical scavengers on the pulmonary thromboembolism in mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluatio | 1993 |
Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischaemia and reperfusion in rats: role of nitric oxide.
Topics: Acetylcholine; Animals; Arginine; Blood Pressure; Coronary Vessels; Disease Models, Animal; Endothel | 1995 |
Cerebrovascular effects of nitric oxide manipulation in spontaneously hypertensive rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; Blood Pressure; Cereb | 1997 |
Nitric oxide donors antagonize N-nitro-L-arginine and haloperidol catalepsy: potential implication for the treatment of Parkinsonism?
Topics: Animals; Arginine; Catalepsy; Disease Models, Animal; Haloperidol; Male; Molsidomine; Nitric Oxide S | 1997 |
Effect of nitric oxide donors and nitric oxide synthase inhibitors in neonatal rat endotoxic shock.
Topics: Animals; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Female; Molsidomine; NG-Nitroarginine | 1999 |
The NO donor molsidomine reduces endothelin-1 gene expression in chronic hypoxic rat lungs.
Topics: Animals; Chronic Disease; Disease Models, Animal; Endothelin-1; Enzyme Inhibitors; Gene Expression R | 2001 |
Prevention of concanavalin A-induced mice hepatitis by molsidomine.
Topics: Alanine Transaminase; Animals; Antibodies; Chemical and Drug Induced Liver Injury; Concanavalin A; D | 2001 |
Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Topics: Animals; Autoimmune Diseases; Disease Models, Animal; Eye Proteins; Humans; Immunization; Interferon | 2001 |
Local delivery of NO-donor molsidomine post-PTA improves haemodynamics, wall mechanics and histomorphometry in atherosclerotic porcine SFA.
Topics: Administration, Cutaneous; Angioplasty, Balloon; Animals; Arteriosclerosis; Combined Modality Therap | 2002 |